Juno Therapeutics Raises $134 Million for Series B Round
Posted on 08/05/2014
Seattle-based Juno Therapeutics Inc., a biotechnology company focusing on novel immunotherapies for cancer, closed a Series B round with US$ 134 million in new investment. In total, Juno has raised over US$ 300 million in the past 12 months – this includes a US$ 176 million Series A round in April. The new capital will […]
- Alaska Permanent Fund Corporation
- Alternatives
- Crestline Investors
- Fred Hutchinson Cancer Research Center
- healthcare
- Jeff Bezos
- Juno Therapeutics
- Leerink Partners
- Seattle
- Venture Capital
